Cutaneous squamous cell carcinoma (cSCC) has become a significant public health issue due to its rapidly rising incidence and an estimated 1.8 million newly diagnosed cases annually. As with other cancers, treatment decisions for patients with cSCC are based primarily on a patient’s risk for poor outcomes.

The risk prediction assay provided significant risk stratification in BE patients with LGD and identified progressors that the experts downstaged to NDBE.

Independent mulit-center study demonstrates risk-aligned treatment plans guided by DecisionDx-Melanoma lead to better patient outcomes.

DecisionDx-Melanoma test results influenced 85% of clinicians’ decisions regarding the SLNB surgical procedure. Use of the test results could help avoid unnecessary procedures in low-risk patients whose tumor biology indicates they could safely forgo the procedure.

A quantitative, multiplexed biomarker imaging approach termed TissueCypher™ that applies systems biology to anatomic pathology.

Using 31-GEP results to guide clinical management and surveillance based on personalized risk of MSS can direct care, improving patient outcomes.

Expert panel of 6 key opinion leaders in dermatology consensus panel unanimously approved eleven usage guidelines and consensus supporting statements for the appropriate use of GEP testing

Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.

Comparison of the i31-GEP for SLNB to the MIA nomogram in patients with T1-T2 tumors with complete data (n=582). The precision of each tool to identify patients with <5% SLN positivity risk was analyzed using 95% confidence intervals.

Study compared the i31-GEP for SLNB with the CP-GEP to identify patients who can safely forego SLNB.

Utilizing patient data provided through collaboration with the NCI SEER program (diagnosis 2016-2018) the 31-GEP class results was a statistically significant independent predictor of MSS and can help identiy patients with low risk of death who may potentially forego unnecessary procedures

TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review of LGD as advocated by all guidelines.